Itraconazole and Norethisterone Drug Interaction

Mechanism of Interaction

Itraconazole is a potent inhibitor of the CYP3A4 enzyme system, which is the primary metabolic pathway for most medications including hormonal contraceptives like norethisterone, reducing the metabolism of norethisterone and leading to elevated serum concentrations 1, 2.
The interaction occurs through both hepatic CYP3A4 inhibition and effects on intestinal drug-metabolizing enzymes, resulting in increased norethisterone levels 1.

Elevated norethisterone levels may cause increased progestin-related side effects, including breakthrough bleeding, breast tenderness, mood changes, and headaches, particularly in patients with additional risk factors 1.
The interaction may also lead to potential thromboembolic risk if norethisterone levels become excessively elevated, particularly in patients with additional risk factors 1.
Unpredictable pharmacokinetics can potentially compromise contraceptive efficacy in some patients, despite elevated norethisterone levels 1.

The American College of Clinical Pharmacology recommends assessing for signs and symptoms of progestin excess, including breakthrough bleeding patterns, breast tenderness, mood disturbances, and headaches, when itraconazole and norethisterone are coadministered 1.
Consider therapeutic drug monitoring for itraconazole to avoid excessive serum concentrations that would amplify the interaction, and review all current medications for potentially deleterious drug interactions before initiating itraconazole therapy 1, 4.
Counsel patients about potential changes in bleeding patterns and increased progestin-related side effects, and consider alternative contraception methods during itraconazole therapy, such as barrier methods as backup 1.

Patients with genetic polymorphisms affecting CYP3A4 enzymes may experience more pronounced interactions between itraconazole and CYP3A4 substrates like norethisterone, although CYP2C19 polymorphisms do not significantly contribute to itraconazole metabolism differences 1, 3.

Failing to recognize the bidirectional nature of hormonal and azole interactions, where both drug levels can be affected, and inadequate patient counseling about potential breakthrough bleeding or contraceptive reliability concerns 1, 2.
Not considering the duration of interaction, which persists as long as both medications are coadministered and for several days after discontinuation due to itraconazole's long half-life, and overlooking the cumulative effect when patients are on multiple CYP3A4 substrates simultaneously with itraconazole 1, 2.